{"gene":"CHI3L1","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2017,"finding":"CHI3L1 (YKL-40) secreted by M2 macrophages binds to IL-13Rα2 on cancer cell plasma membranes, activating MAPK signaling and upregulating matrix metalloproteinase gene expression to promote gastric and breast cancer metastasis.","method":"GST pull-down assay identifying IL-13Rα2 as receptor; in vitro and in vivo metastasis models; western blot for MAPK pathway activation","journal":"Journal of hematology & oncology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding assay plus in vivo validation with multiple orthogonal methods","pmids":["28143526"],"is_preprint":false},{"year":2021,"finding":"CHI3L1 regulates PD-L1, PD-L2, PD-1, LAG3, and TIM3 expression in melanoma and macrophages; IFN-γ-stimulated macrophage PD-L1 expression is dependent on CHI3L1; RIG-like helicase innate immunity suppresses CHI3L1 and PD-L1. Bispecific antibodies simultaneously targeting CHI3L1 and PD-1 show synergistic antitumor effects in T cell-tumor cell cocultures and in vivo metastasis models.","method":"Antibody blockade, T cell-tumor cell coculture cytotoxicity assay, in vivo melanoma metastasis models, gene expression analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in vitro and in vivo with mechanistic pathway identification","pmids":["34720089"],"is_preprint":false},{"year":2023,"finding":"CHI3L1 promotes neutrophil recruitment and neutrophil extracellular trap (NET) formation in triple-negative breast cancer, which blocks CD8+ T cell tumor infiltration. Chi3l1 expression is regulated downstream of Stat3 in breast tumors.","method":"Chi3l1 ablation in PyMT breast cancer mouse model; immune cell infiltration analysis; NET formation assays; Stat3 knockout tumor profiling","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic ablation model with specific cellular phenotype and mechanistic pathway placement","pmids":["38039967"],"is_preprint":false},{"year":2020,"finding":"Chi3l1 deletion in mice suppresses glial phagocytic activation; Chi3l1 knockdown increases phagocytosis of zymosan particles and β-amyloid peptide in astrocytes and microglia in vitro, and decreases amyloid plaque burden in APP/PS1 mice. Chi3l1 expression is regulated by the circadian clock via BMAL1/CLOCK/NPAS2 and PER1/PER2.","method":"Chi3l1 knockout mice crossed with APP/PS1 AD model; in vitro phagocytosis assay; circadian clock gene deletion; inflammatory induction experiments in astrocytes","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including genetic knockout, in vitro assays, and in vivo AD model with specific phenotypic readouts","pmids":["33328329"],"is_preprint":false},{"year":2015,"finding":"Cytokine-driven YKL-40 expression in astrocytes requires both STAT3 and NF-κB binding elements of the YKL-40 promoter; specifically IL-1 and oncostatin M promote RelB/p50 complex formation which directly binds the YKL-40 promoter. Expression is independent of p65 NF-κB subunit.","method":"Promoter reporter assays, dominant-negative IκBα, constitutively active STAT3, chromatin immunoprecipitation for RelB/p50 binding to YKL-40 promoter, primary human and mouse astrocytes","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — promoter mutagenesis, direct ChIP of transcription factor binding, multiple cell systems","pmids":["25681350"],"is_preprint":false},{"year":2023,"finding":"Chi3l1 binds CD44 on glioma stem cells (GSCs) and induces phosphorylation and nuclear translocation of β-catenin, Akt, and STAT3, driving GSCs toward a mesenchymal state. Chi3l1 increases promoter accessibility at MAZ transcription factor sites; MAZ deficiency rescues Chi3L1-induced increase of GSC self-renewal.","method":"Binding assay (Chi3l1 to CD44), phosphorylation western blots, scRNA-seq with RNA velocity, ATAC-seq, MAZ inhibition, in vivo tumor growth with blocking antibody","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding identified, multiple orthogonal methods including ATAC-seq and scRNA-seq, in vivo validation","pmids":["37101376"],"is_preprint":false},{"year":2023,"finding":"CHI3L1 secreted by activated astrocytes engages the CRTH2 receptor on neural stem cells and dampens β-catenin signaling, inhibiting proliferation and neuronal differentiation of neural stem cells in the context of neuromyelitis optica (NMO). Blocking CHI3L1/CRTH2/β-catenin restores neurogenesis and improves cognitive deficits.","method":"CHI3L1 knockdown in astrocytes (in vitro and in vivo NMO mouse model), neural stem cell proliferation/differentiation assays, β-catenin signaling analysis, CRTH2 blocking experiments","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — receptor identification, signaling mechanism defined, in vivo rescue with multiple readouts","pmids":["37756391"],"is_preprint":false},{"year":2024,"finding":"Astrocyte-derived CHI3L1 interacts with CRTH2/RAGE receptors and attenuates β-catenin signaling in the demyelinated hippocampus, impairing neural stem cell proliferation, neuronal differentiation, dendritic growth, and spine formation. Astrocytic deletion of CHI3L1 mitigates neurogenic deficits and cognitive dysfunction.","method":"Astrocyte-specific CHI3L1 deletion in demyelination mouse model, receptor co-immunoprecipitation (CRTH2/RAGE), β-catenin signaling assays, neural stem cell assays, cognitive behavioral tests","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — receptor interaction identified, signaling mechanism, astrocyte-specific KO with defined cellular and behavioral phenotype","pmids":["38733586"],"is_preprint":false},{"year":2021,"finding":"CHI3L1 interacts with BMPRIa on osteoblasts, increasing surface expression of BMPRIa and promoting BMP2 signaling and RUNX2 expression to induce osteoblast differentiation. Chi3l1 KO mice show impaired osteoblast differentiation and aging-related osteoporosis with decreased OPG and increased osteoclast numbers.","method":"Co-immunoprecipitation of Chi3l1 with BMPRIa, Chi3l1 KO mouse bone phenotype, primary osteoblast differentiation assays, western blot for BMP2 signaling","journal":"Pharmacological research","confidence":"High","confidence_rationale":"Tier 2 — co-IP identifying binding partner, KO mouse model with defined bone phenotype, signaling pathway analysis","pmids":["36064078"],"is_preprint":false},{"year":2020,"finding":"CHI3L1 activates AKT3 signaling in nucleus pulposus (NP) cells to protect against intervertebral disc degeneration. CHI3L1 expression is NP tissue-specific and increases during degeneration; overexpression decreases catabolism and increases anabolism of extracellular matrix via AKT3.","method":"High-throughput label-free proteomics, RNA sequencing, CHI3L1 overexpression and siRNA knockdown in NP cells, AKT3 phosphorylation analysis, validation in human and mouse degenerated NP tissues","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — proteomic identification, RNA-seq, gain/loss-of-function with specific pathway readout, validated in vivo","pmids":["31997395"],"is_preprint":false},{"year":2021,"finding":"A small molecule (K284) that binds to the chitin-binding domain (CBD) of CHI3L1 prevents CHI3L1 binding to IL-13Rα2, thereby suppressing JNK-AP-1 signaling and inhibiting lung metastasis and cancer cell growth.","method":"In vitro binding assay of K284 to CHI3L1 CBD, CHI3L1-IL-13Rα2 binding competition assay, JNK-AP-1 signaling analysis, in vitro and in vivo lung metastasis models","journal":"Molecular oncology","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding domain identified, competitive receptor-ligand assay, signaling pathway defined, in vivo validation","pmids":["34758182"],"is_preprint":false},{"year":2020,"finding":"YKL-40 promotes airway remodeling in asthma by increasing airway smooth muscle mass, inducing EMT and sub-epithelial fibrosis through activation of FAK and MAPK signaling pathways. Inhibiting FAK or MAPK significantly ameliorates YKL-40-induced airway remodeling in vitro and in vivo.","method":"YKL-40 treatment of airway smooth muscle cells, FAK/MAPK inhibitor experiments, asthma mouse model, EMT marker analysis","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway defined with inhibitor rescue, in vitro and in vivo, single lab","pmids":["32286145"],"is_preprint":false},{"year":2018,"finding":"CHI3L1 promotes hepatocellular carcinoma cell growth, migration, and invasion by activating TGF-β signaling pathways, including phosphorylation of SMAD2 and SMAD3. CHI3L1 overexpression affects genes involved in cell-cell adhesion, extracellular exosome, and adherens junction.","method":"CHI3L1 overexpression in HCC cell lines, RNA-seq gene expression profiling, western blot for SMAD2/3 phosphorylation, in vivo tumor models","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function with RNA-seq and signaling validation, in vivo confirmation, single lab","pmids":["30301907"],"is_preprint":false},{"year":2006,"finding":"HC-gp39 (CHI3L1) induces SOX9 and type II collagen expression in chondrocytes via MAP kinase (ERK1/2 phosphorylation) and PI3 kinase (AKT phosphorylation) signaling pathways, promoting chondrocyte differentiation.","method":"Purified HC-gp39 treatment of primary neonatal mouse rib chondrocytes, phosphorylation-specific western blot, selective signaling inhibitors","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway defined with inhibitors and phosphoprotein analysis, single lab","pmids":["16949314"],"is_preprint":false},{"year":2023,"finding":"YKL-40-expressing M2-like macrophages in gallbladder cancer induce tumor cell secretion of GDF15, which cooperates with YKL-40 to promote PD-L1 expression via PI3K, AKT, and/or Erk activation, leading to T cell cytotoxicity inhibition and tumor immune evasion. YKL-40 shRNA reprogrammed M2-like THP-1 cells to M1-like macrophages.","method":"Single-cell transcriptome analysis, YKL-40 shRNA knockdown, PI3K/AKT/Erk signaling analysis by western blot, co-culture assays for T cell function","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway defined, single-cell RNA-seq, shRNA knockdown with phenotypic readout, single lab","pmids":["37088328"],"is_preprint":false},{"year":2024,"finding":"CHI3L1 directly binds the coiled-coil domain (CCD) of STAT3 to enhance its phosphorylation, nuclear localization, and transcriptional activity. CHI3L1 and OPN/ITGB1 form a positive feedback loop maintaining NF-κB and STAT3 pathway activation in glioblastoma mesenchymal transition. Hygromycin B disrupts the CHI3L1-STAT3 interaction.","method":"scMulti-omics, direct binding assay of CHI3L1 to STAT3 CCD, phosphorylation and nuclear localization analysis, C57BL/6 and NSG mouse tumor models, pharmacological inhibition with hygromycin B","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1–2 — direct protein-domain binding identified, mechanistic pathway in vitro and in vivo, pharmacological validation","pmids":["39933531"],"is_preprint":false},{"year":2010,"finding":"YKL-40 knockdown (siRNA) in glioblastoma U87 cells arrests the cell cycle in G1 phase and decreases phosphorylated ERK1/2 and AKT levels. YKL-40 promotes glioma cell proliferation through activation of MAPK and AKT pathways; resveratrol represses YKL-40 via the ERK1/2 pathway.","method":"siRNA knockdown, flow cytometry cell cycle analysis, western blot for phospho-ERK1/2, phospho-AKT, p38 MAPK inhibitor (SB203580) rescue experiments","journal":"Cancer; BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with pathway readout, pharmacological inhibitor rescue, replicated across two studies","pmids":["20499402","21029458"],"is_preprint":false},{"year":2023,"finding":"CHI3L1 depletion in cancer cells induces ER stress through PERK-eIF2α-ATF4 signaling activation, leading to ER stress-mediated apoptosis. CHI3L1 is localized in the ER. Superoxide dismutase-1 (SOD1) was identified as a novel interacting protein of CHI3L1; CHI3L1 depletion increases SOD1 expression resulting in ER stress and apoptosis in cancer cells.","method":"LC-MS/MS proteomics in CHI3L1-overexpressing cells, co-immunoprecipitation of CHI3L1 and SOD1, ER stress marker analysis, CHI3L1-KO mouse tumor models, SOD1 siRNA rescue experiments","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1–2 — MS-based interactome, co-IP for binding partner, in vivo KO model, rescue experiments, multiple orthogonal methods","pmids":["37215572"],"is_preprint":false},{"year":2021,"finding":"Anti-CHI3L1 antibody inhibits lung tumor growth and metastasis by blocking STAT6-dependent M2 macrophage polarization. Proteomics analysis revealed that plasminogen (PLG) interacts with CHI3L1 and affects M2 polarization.","method":"Anti-CHI3L1 humanized antibody in lung cancer mouse model, STAT6 pathway analysis, proteomics identification of PLG-CHI3L1 interaction","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo antibody blockade with defined pathway, proteomics-identified binding partner, single lab","pmids":["34861103"],"is_preprint":false},{"year":2022,"finding":"CHI3L1 inhibits ICOS, ICOSL, and CD28 expression while stimulating CTLA-4 and B7 ligands in melanoma lung metastasis. Bispecific antibodies targeting both CHI3L1 and CTLA-4 synergistically induce cytotoxic T cell-mediated tumor cell death and heighten PTEN expression.","method":"CHI3L1 antibody blockade, T cell-tumor cell cocultures, melanoma lung metastasis mouse model, bispecific antibody treatment, flow cytometry for checkpoint markers","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional cell assays, in vivo model, checkpoint marker regulation defined, single lab","pmids":["36618349"],"is_preprint":false},{"year":2023,"finding":"pSTAT3+ reactive astrocytes secrete CHI3L1 (a STAT3 transcriptional target) at the brain-tumor interface; this CHI3L1 promotes highly invasive brain metastasis invasion into the brain parenchyma. Recombinant CHI3L1 alone or STAT3 activation induced cancer cell invasion into brain parenchyma in a brain slice-tumor co-culture assay.","method":"Single-cell RNA sequencing, immunohistochemistry, STAT3 inhibition and genetic ablation, brain slice-tumor plug co-culture invasion assay, PDX and syngeneic mouse models","journal":"Neuro-oncology","confidence":"High","confidence_rationale":"Tier 2 — STAT3 as upstream transcriptional regulator of CHI3L1 established, recombinant protein functional assay, genetic ablation, in vivo validation, multiple orthogonal methods","pmids":["38271182"],"is_preprint":false},{"year":2024,"finding":"CHI3L1 gene expression functionally influences tumor microtube (TM) network connectivity in glioblastoma; Chi3l1 serves as a robust molecular marker of TM connectivity associated with the mesenchymal subtype.","method":"scRNA-seq from xenografted primary GB cells with dye uptake connectivity assay, calcium imaging, clinical correlation in large GB cohorts","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — functional connectivity assay combined with scRNA-seq, validated clinically, single lab","pmids":["38320988"],"is_preprint":false},{"year":2023,"finding":"Astrocyte-derived CHI3L1 expression promotes Aβ accumulation by suppressing glial phagocytosis of amyloid. Astrocyte-specific YKL-40 knockout in 5xFAD mice reduces amyloid plaque deposition through enhanced Aβ uptake, increased Aβ degradation rate, and lysosomal acidification in YKL-40 KO astrocytes. In primary neurons, YKL-40 combined with Aβ induces synaptic degeneration and impairs electrical parameters.","method":"Astrocyte-specific Chi3l1 KO in 5xFAD mice, primary astrocyte phagocytosis assay, Aβ uptake/degradation assay, lysosomal acidification assay, primary neuron treatment with recombinant YKL-40","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 — astrocyte-specific genetic KO in AD model, in vitro mechanistic assays for phagocytosis and lysosomal function, multiple orthogonal methods","pmids":["38042775"],"is_preprint":false},{"year":2017,"finding":"Molecular dynamics simulations predict that hyaluronan is the preferred physiological ligand for YKL-40 over chito-oligosaccharides and collagen-like peptides, based on calculated free energies of binding. Heparin binds non-specifically at the YKL-40 surface.","method":"Molecular dynamics simulations with free energy calculations for multiple ligands","journal":"The Journal of biological chemistry","confidence":"Low","confidence_rationale":"Tier 4 — computational prediction only, no experimental validation","pmids":["28053085"],"is_preprint":false},{"year":2023,"finding":"P. gingivalis increases CHI3L1 expression in iNKT cells, impairing their cytotoxic (lytic) functions and promoting colorectal cancer immune evasion. Neutralization of CHI3L1 restored iNKT cell cytotoxic functions.","method":"In vivo P. gingivalis CRC mouse model, in vitro iNKT cell stimulation assays, CHI3L1 neutralizing antibody, cytotoxicity assays","journal":"Gut microbes","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro models, neutralization rescue, defined cellular mechanism, single lab","pmids":["39132842"],"is_preprint":false},{"year":2021,"finding":"Nrf2 overexpression suppresses CHI3L1 expression in synoviocytes stimulated with LPS; LPS-induced CHI3L1 increase correlates with ROS and inflammatory cytokine (TNF-α, IL-1β, IL-6) production. Nrf2 acts as a negative regulator of CHI3L1 in post-traumatic osteoarthritis.","method":"Nrf2 overexpression lentiviral vector in PTOA mouse model (intra-articular injection), LPS-stimulated murine synoviocyte in vitro model, ELISA/western blot for CHI3L1 and inflammatory markers","journal":"Journal of inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function in vivo and in vitro with defined regulatory relationship, single lab","pmids":["34466014"],"is_preprint":false},{"year":2023,"finding":"M2 macrophage-secreted CHI3L1 promotes hepatocyte recovery from ischemia-reperfusion injury by improving hepatocellular lipid metabolism. Downstream of CX3CR1 deficiency and RelA suppression, M2 macrophages upregulate CHIL3/CHI3L1 which improves mitochondrial function and reduces injury in cultured hepatocytes.","method":"CX3CR1 KO mice, 5-ALA treatment, M2 macrophage polarization assay, hepatocyte co-culture with recombinant CHIL3/CHI3L1, metabolic and mitochondrial function assays","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO model, recombinant protein treatment, mechanistic pathway identified, single lab","pmids":["37771779"],"is_preprint":false}],"current_model":"CHI3L1/YKL-40 is a secreted, chitin-binding glycoprotein (lacking catalytic chitinase activity) produced by activated astrocytes, macrophages, and tumor cells that acts extracellularly through multiple receptors—including IL-13Rα2, CD44, CRTH2, RAGE, and BMPRIa—to activate downstream signaling cascades (MAPK, PI3K/AKT, STAT3, NF-κB/RelB/p50, TGF-β/SMAD, BMP2, β-catenin, and JNK-AP-1), regulate innate immune cell polarization (M2 macrophage programming, neutrophil NET formation), suppress glial and neural stem cell phagocytic/neurogenic activity, modulate immune checkpoint expression (PD-L1, CTLA-4), and promote tumor invasion, metastasis, and extracellular matrix remodeling; its transcription is regulated by IL-1/IL-6 family cytokines via STAT3 and RelB/p50 complexes, and by the circadian clock via BMAL1/CLOCK."},"narrative":{"teleology":[{"year":2006,"claim":"Establishing that CHI3L1 is not merely a biomarker but an active signaling ligand: exogenous HC-gp39 induced SOX9 and collagen II in chondrocytes through ERK1/2 and AKT phosphorylation, demonstrating that the catalytically inactive lectin has direct cell-signaling capacity.","evidence":"Purified protein treatment of primary chondrocytes with pharmacological inhibitors and phospho-western blot","pmids":["16949314"],"confidence":"Medium","gaps":["Receptor mediating chondrocyte signaling was not identified","Mechanism of downstream SOX9 transcription not resolved"]},{"year":2010,"claim":"Loss-of-function studies confirmed CHI3L1 as a cell-autonomous driver of glioblastoma proliferation via MAPK/AKT, linking the secreted protein to tumor cell cycle progression.","evidence":"siRNA knockdown in U87 glioblastoma cells with cell cycle analysis and phospho-ERK/AKT western blot","pmids":["20499402","21029458"],"confidence":"Medium","gaps":["Receptor(s) on glioblastoma cells mediating autocrine signaling not identified","Downstream transcriptional targets driving G1 arrest not characterized"]},{"year":2015,"claim":"The transcriptional logic of CHI3L1 induction was resolved: IL-1/oncostatin M-driven expression in astrocytes requires cooperative STAT3 and RelB/p50 NF-κB promoter engagement, with RelB/p50 (not p65) directly binding the CHI3L1 promoter.","evidence":"Promoter-reporter mutagenesis, ChIP for RelB/p50, dominant-negative IκBα in primary human and mouse astrocytes","pmids":["25681350"],"confidence":"High","gaps":["Whether RelB/p50 regulation operates in non-astrocyte cell types not tested","Epigenetic regulation of the locus not addressed"]},{"year":2017,"claim":"The first bona fide cell-surface receptor for CHI3L1 was identified: IL-13Rα2 on cancer cells, establishing a ligand-receptor axis by which M2 macrophage-derived CHI3L1 activates MAPK signaling to drive metastasis.","evidence":"GST pull-down identifying IL-13Rα2, MAPK pathway activation by western blot, in vivo metastasis models","pmids":["28143526"],"confidence":"High","gaps":["Whether IL-13Rα2 mediates CHI3L1 signaling in non-cancer contexts not established","Co-receptors or adaptor mechanisms downstream of IL-13Rα2 not defined"]},{"year":2020,"claim":"CHI3L1 was established as a suppressor of glial phagocytosis relevant to Alzheimer's disease, and its expression was linked to circadian clock control via BMAL1/CLOCK, revealing a time-of-day dimension to its regulation.","evidence":"Chi3l1 KO crossed with APP/PS1 mice; in vitro phagocytosis of Aβ/zymosan; circadian gene deletion in astrocytes","pmids":["33328329"],"confidence":"High","gaps":["Receptor through which CHI3L1 suppresses phagocytosis not identified in this study","Mechanism linking circadian transcription factors to CHI3L1 promoter occupancy not shown by ChIP"]},{"year":2021,"claim":"CHI3L1 was revealed as an upstream regulator of immune checkpoint molecules (PD-L1, PD-1, LAG3, TIM3), establishing it as an immunomodulatory node that could be co-targeted with checkpoint blockade for synergistic anti-tumor effects.","evidence":"Antibody blockade, T cell–tumor coculture cytotoxicity, in vivo melanoma metastasis, bispecific CHI3L1/PD-1 antibody","pmids":["34720089"],"confidence":"High","gaps":["Signaling pathway connecting CHI3L1 to transcriptional regulation of PD-L1/LAG3/TIM3 not fully defined","Whether checkpoint regulation is receptor-specific or shared across CHI3L1 receptors unknown"]},{"year":2021,"claim":"A second receptor axis was defined: CHI3L1 binds BMPRIa on osteoblasts to potentiate BMP2/RUNX2 osteoblast differentiation, and Chi3l1 KO mice develop osteoporosis, demonstrating a physiological role beyond inflammation and cancer.","evidence":"Co-immunoprecipitation of Chi3l1–BMPRIa, Chi3l1 KO bone phenotyping, primary osteoblast differentiation assays","pmids":["36064078"],"confidence":"High","gaps":["Structural basis of CHI3L1–BMPRIa interaction not resolved","Whether BMPRIa mediates CHI3L1 signaling in non-bone tissues not tested"]},{"year":2021,"claim":"The chitin-binding domain was validated as a druggable surface: a small molecule (K284) competitively blocks CHI3L1 binding to IL-13Rα2, suppressing JNK-AP-1 signaling and lung metastasis.","evidence":"In vitro binding and competition assays, JNK-AP-1 signaling analysis, in vivo lung metastasis models","pmids":["34758182"],"confidence":"High","gaps":["Selectivity of K284 for CHI3L1 over other GH18 family members not shown","Whether K284 blocks CHI3L1 binding to other receptors (CD44, CRTH2, BMPRIa) not assessed"]},{"year":2023,"claim":"Additional receptor diversity was uncovered: CHI3L1 engages CD44 on glioma stem cells to activate β-catenin/Akt/STAT3, chromatin remodeling at MAZ sites, and mesenchymal transition; and CRTH2 on neural stem cells to suppress β-catenin-dependent neurogenesis.","evidence":"Binding assays, ATAC-seq, scRNA-seq with RNA velocity for CD44 axis; CRTH2 blocking, β-catenin analysis, NMO mouse model for CRTH2 axis","pmids":["37101376","37756391"],"confidence":"High","gaps":["Structural determinants distinguishing CHI3L1 binding to CD44 vs. CRTH2 unknown","Whether CHI3L1 signals through CD44 and CRTH2 simultaneously on the same cell not tested"]},{"year":2023,"claim":"In the tumor immune microenvironment, CHI3L1 was shown to promote neutrophil recruitment and NET formation that physically excludes CD8+ T cells, establishing a STAT3-CHI3L1-NET immunosuppressive circuit in triple-negative breast cancer.","evidence":"Chi3l1 genetic ablation in PyMT breast cancer model, immune cell infiltration analysis, NET assays, Stat3 KO tumor profiling","pmids":["38039967"],"confidence":"High","gaps":["Receptor on neutrophils that mediates CHI3L1-induced NET formation not identified","Whether CHI3L1-driven NETs operate in non-breast tumor types not tested"]},{"year":2023,"claim":"An intracellular role emerged: CHI3L1 resides in the ER and interacts with SOD1; its depletion triggers PERK-eIF2α-ATF4 ER stress-mediated apoptosis, suggesting functions beyond secreted signaling.","evidence":"LC-MS/MS proteomics, co-IP of CHI3L1–SOD1, ER stress marker analysis, CHI3L1-KO mouse tumors, SOD1 siRNA rescue","pmids":["37215572"],"confidence":"High","gaps":["Whether ER-resident CHI3L1 is a distinct pool from secreted CHI3L1 not clarified","Structural basis of CHI3L1–SOD1 interaction unknown","Generalizability of ER stress phenotype to non-cancer cells not tested"]},{"year":2024,"claim":"A direct intracellular signaling mechanism was identified: CHI3L1 binds the coiled-coil domain of STAT3 to promote its phosphorylation and nuclear translocation, forming a positive feedback loop with OPN/ITGB1 and NF-κB in glioblastoma mesenchymal transition.","evidence":"scMulti-omics, domain-specific binding assays, phosphorylation/nuclear localization analysis, hygromycin B as pharmacological disruptor, mouse tumor models","pmids":["39933531"],"confidence":"High","gaps":["Whether direct CHI3L1–STAT3 binding occurs in non-glioblastoma cells unknown","How CHI3L1 accesses intracellular STAT3 (internalization vs. de novo synthesis) not resolved"]},{"year":null,"claim":"Major unresolved questions include: (1) how CHI3L1 selects among its multiple receptors (IL-13Rα2, CD44, CRTH2, RAGE, BMPRIa) in different cellular contexts; (2) whether its intracellular ER/STAT3-binding functions are independent of its secreted extracellular receptor-mediated signaling; and (3) whether a unifying structural model explains differential ligand-receptor engagement through the chitin-binding domain.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural co-crystal with any receptor","No systematic comparison of receptor affinities or competition","Intracellular vs. extracellular functional partitioning not delineated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,5,6,7,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,14,19]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,6,8,10]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,6,7,8,9,22]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,6,7,8,10,13,15,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,14,18,19,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,2,5,12,15,20,21]}],"complexes":[],"partners":["IL13RA2","CD44","PTGDR2","AGER","BMPR1A","STAT3","SOD1","PLG"],"other_free_text":[]},"mechanistic_narrative":"CHI3L1 (YKL-40) is a secreted glycoprotein lacking chitinase catalytic activity that functions as a multireceptor ligand to regulate innate immunity, tissue remodeling, and tumor progression across diverse cellular contexts. It signals through IL-13Rα2 to activate MAPK and JNK-AP-1 pathways promoting cancer metastasis [PMID:28143526, PMID:34758182], through CD44 to drive β-catenin/Akt/STAT3-dependent glioma stem cell self-renewal [PMID:37101376], and through CRTH2/RAGE to suppress β-catenin signaling and inhibit neural stem cell neurogenesis [PMID:37756391, PMID:38733586]; it also directly binds the STAT3 coiled-coil domain to enhance STAT3 phosphorylation and nuclear translocation in glioblastoma [PMID:39933531]. In the immune microenvironment, CHI3L1 promotes M2 macrophage polarization, neutrophil extracellular trap formation that excludes CD8+ T cells, and upregulation of immune checkpoint molecules including PD-L1 and CTLA-4 [PMID:34720089, PMID:38039967, PMID:36618349]; in astrocytes, it suppresses phagocytic clearance of amyloid-β, and its transcription is controlled by STAT3, RelB/p50 NF-κB complexes, and the BMAL1/CLOCK circadian machinery [PMID:25681350, PMID:33328329, PMID:38042775]."},"prefetch_data":{"uniprot":{"accession":"P36222","full_name":"Chitinase-3-like protein 1","aliases":["39 kDa synovial protein","Cartilage glycoprotein 39","CGP-39","GP-39","hCGP-39","YKL-40"],"length_aa":383,"mass_kda":42.6,"function":"Carbohydrate-binding lectin with a preference for chitin. Has no chitinase activity. May play a role in tissue remodeling and in the capacity of cells to respond to and cope with changes in their environment. Plays a role in T-helper cell type 2 (Th2) inflammatory response and IL-13-induced inflammation, regulating allergen sensitization, inflammatory cell apoptosis, dendritic cell accumulation and M2 macrophage differentiation. Facilitates invasion of pathogenic enteric bacteria into colonic mucosa and lymphoid organs. Mediates activation of AKT1 signaling pathway and subsequent IL8 production in colonic epithelial cells. Regulates antibacterial responses in lung by contributing to macrophage bacterial killing, controlling bacterial dissemination and augmenting host tolerance. Also regulates hyperoxia-induced injury, inflammation and epithelial apoptosis in lung","subcellular_location":"Secreted, extracellular space; Cytoplasm; Cytoplasm, perinuclear region; Endoplasmic reticulum","url":"https://www.uniprot.org/uniprotkb/P36222/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CHI3L1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CHI3L1","total_profiled":1310},"omim":[{"mim_id":"620290","title":"TRANSMEMBRANE PROTEIN 219; TMEM219","url":"https://www.omim.org/entry/620290"},{"mim_id":"615692","title":"CHITINASE DOMAIN-CONTAINING PROTEIN 1; CHID1","url":"https://www.omim.org/entry/615692"},{"mim_id":"611960","title":"ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 7; ASRT7","url":"https://www.omim.org/entry/611960"},{"mim_id":"601525","title":"CHITINASE 3-LIKE 1; CHI3L1","url":"https://www.omim.org/entry/601525"},{"mim_id":"600807","title":"ASTHMA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/600807"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"choroid plexus","ntpm":347.9},{"tissue":"liver","ntpm":423.6}],"url":"https://www.proteinatlas.org/search/CHI3L1"},"hgnc":{"alias_symbol":["GP39","YKL40","YK-40"],"prev_symbol":[]},"alphafold":{"accession":"P36222","domains":[{"cath_id":"3.20.20.80","chopping":"22-260_330-380","consensus_level":"medium","plddt":97.1291,"start":22,"end":380}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P36222","model_url":"https://alphafold.ebi.ac.uk/files/AF-P36222-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P36222-F1-predicted_aligned_error_v6.png","plddt_mean":94.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CHI3L1","jax_strain_url":"https://www.jax.org/strain/search?query=CHI3L1"},"sequence":{"accession":"P36222","fasta_url":"https://rest.uniprot.org/uniprotkb/P36222.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P36222/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P36222"}},"corpus_meta":[{"pmid":"7678782","id":"PMC_7678782","title":"The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7678782","citation_count":748,"is_preprint":false},{"pmid":"8717526","id":"PMC_8717526","title":"Immune regulation by CD40 and its ligand GP39.","date":"1996","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8717526","citation_count":504,"is_preprint":false},{"pmid":"28143526","id":"PMC_28143526","title":"Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28143526","citation_count":385,"is_preprint":false},{"pmid":"7516405","id":"PMC_7516405","title":"gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7516405","citation_count":367,"is_preprint":false},{"pmid":"8103067","id":"PMC_8103067","title":"The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8103067","citation_count":333,"is_preprint":false},{"pmid":"7693850","id":"PMC_7693850","title":"In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.","date":"1993","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7693850","citation_count":312,"is_preprint":false},{"pmid":"7529804","id":"PMC_7529804","title":"Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7529804","citation_count":296,"is_preprint":false},{"pmid":"8560571","id":"PMC_8560571","title":"CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway.","date":"1996","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/8560571","citation_count":266,"is_preprint":false},{"pmid":"10188896","id":"PMC_10188896","title":"Serum YKL-40 and colorectal cancer.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10188896","citation_count":167,"is_preprint":false},{"pmid":"33328329","id":"PMC_33328329","title":"Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis.","date":"2020","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33328329","citation_count":159,"is_preprint":false},{"pmid":"8809473","id":"PMC_8809473","title":"Functions of CD40 and its ligand, gp39 (CD40L).","date":"1996","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8809473","citation_count":139,"is_preprint":false},{"pmid":"19792974","id":"PMC_19792974","title":"Plasma YKL-40: a potential new cancer biomarker?","date":"2009","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19792974","citation_count":133,"is_preprint":false},{"pmid":"7595208","id":"PMC_7595208","title":"An essential role for gp39, the ligand for CD40, in thymic selection.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7595208","citation_count":132,"is_preprint":false},{"pmid":"15771622","id":"PMC_15771622","title":"Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells.","date":"2005","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/15771622","citation_count":110,"is_preprint":false},{"pmid":"15829322","id":"PMC_15829322","title":"Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer.","date":"2005","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/15829322","citation_count":108,"is_preprint":false},{"pmid":"28592456","id":"PMC_28592456","title":"CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.","date":"2017","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28592456","citation_count":107,"is_preprint":false},{"pmid":"38039967","id":"PMC_38039967","title":"The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38039967","citation_count":101,"is_preprint":false},{"pmid":"29773027","id":"PMC_29773027","title":"Functions of CD40 and Its Ligand, gp39 (CD40L).","date":"2017","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29773027","citation_count":90,"is_preprint":false},{"pmid":"23149946","id":"PMC_23149946","title":"Evaluation of CHI3L-1 and CHIT-1 expression in differentiated and polarized macrophages.","date":"2013","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23149946","citation_count":84,"is_preprint":false},{"pmid":"37690071","id":"PMC_37690071","title":"Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression.","date":"2023","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/37690071","citation_count":83,"is_preprint":false},{"pmid":"8642284","id":"PMC_8642284","title":"The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8642284","citation_count":83,"is_preprint":false},{"pmid":"26310833","id":"PMC_26310833","title":"YKL-40/CHI3L1 drives inflammation on the road of tumor progression.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26310833","citation_count":82,"is_preprint":false},{"pmid":"20347092","id":"PMC_20347092","title":"Increased YKL-40 expression in patients with carotid atherosclerosis.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/20347092","citation_count":77,"is_preprint":false},{"pmid":"30291183","id":"PMC_30291183","title":"CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.","date":"2018","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30291183","citation_count":75,"is_preprint":false},{"pmid":"9263008","id":"PMC_9263008","title":"Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice.","date":"1997","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9263008","citation_count":68,"is_preprint":false},{"pmid":"30301907","id":"PMC_30301907","title":"CHI3L1 promotes tumor progression by activating TGF-β signaling pathway in hepatocellular carcinoma.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30301907","citation_count":67,"is_preprint":false},{"pmid":"28989002","id":"PMC_28989002","title":"CHI3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients.","date":"2017","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/28989002","citation_count":66,"is_preprint":false},{"pmid":"19134206","id":"PMC_19134206","title":"YKL-40 tissue expression and plasma levels in patients with ovarian cancer.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19134206","citation_count":62,"is_preprint":false},{"pmid":"25308850","id":"PMC_25308850","title":"Expression of CHI3L1 and CHIT1 in osteoarthritic rat cartilage model. A morphological study.","date":"2014","source":"European journal of histochemistry : EJH","url":"https://pubmed.ncbi.nlm.nih.gov/25308850","citation_count":62,"is_preprint":false},{"pmid":"34720089","id":"PMC_34720089","title":"CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34720089","citation_count":57,"is_preprint":false},{"pmid":"25681350","id":"PMC_25681350","title":"RelB/p50 complexes regulate cytokine-induced YKL-40 expression.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25681350","citation_count":55,"is_preprint":false},{"pmid":"7543281","id":"PMC_7543281","title":"Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7543281","citation_count":55,"is_preprint":false},{"pmid":"30901080","id":"PMC_30901080","title":"Astrogliogenesis in human fetal brain: complex spatiotemporal immunoreactivity patterns of GFAP, S100, AQP4 and YKL-40.","date":"2019","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/30901080","citation_count":55,"is_preprint":false},{"pmid":"29981861","id":"PMC_29981861","title":"Combined Assessment of Serum Periostin and YKL-40 May Identify Asthma-COPD Overlap.","date":"2018","source":"The journal of allergy and clinical immunology. In practice","url":"https://pubmed.ncbi.nlm.nih.gov/29981861","citation_count":52,"is_preprint":false},{"pmid":"16882657","id":"PMC_16882657","title":"The phylogenetically conserved molluscan chitinase-like protein 1 (Cg-Clp1), homologue of human HC-gp39, stimulates proliferation and regulates synthesis of extracellular matrix components of mammalian chondrocytes.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16882657","citation_count":50,"is_preprint":false},{"pmid":"17227236","id":"PMC_17227236","title":"Is YKL-40 a new therapeutic target in cancer?","date":"2007","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/17227236","citation_count":48,"is_preprint":false},{"pmid":"27121858","id":"PMC_27121858","title":"High CHI3L1 expression is associated with glioma patient survival.","date":"2016","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27121858","citation_count":47,"is_preprint":false},{"pmid":"35813465","id":"PMC_35813465","title":"The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35813465","citation_count":46,"is_preprint":false},{"pmid":"33658322","id":"PMC_33658322","title":"Potential Role of CHI3L1+ Astrocytes in Progression in MS.","date":"2021","source":"Neurology(R) neuroimmunology & neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/33658322","citation_count":46,"is_preprint":false},{"pmid":"37088328","id":"PMC_37088328","title":"YKL-40 derived from infiltrating macrophages cooperates with GDF15 to establish an immune suppressive microenvironment in gallbladder cancer.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37088328","citation_count":46,"is_preprint":false},{"pmid":"37101376","id":"PMC_37101376","title":"Chi3l1 Is a Modulator of Glioma Stem Cell States and a Therapeutic Target in Glioblastoma.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37101376","citation_count":45,"is_preprint":false},{"pmid":"34861103","id":"PMC_34861103","title":"Anti-Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarization.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34861103","citation_count":44,"is_preprint":false},{"pmid":"37756391","id":"PMC_37756391","title":"CHI3L1 signaling impairs hippocampal neurogenesis and cognitive function in autoimmune-mediated neuroinflammation.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37756391","citation_count":43,"is_preprint":false},{"pmid":"32861071","id":"PMC_32861071","title":"CHI3L1 in the pathophysiology and diagnosis of liver diseases.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32861071","citation_count":41,"is_preprint":false},{"pmid":"24635545","id":"PMC_24635545","title":"Analysis of YKL-40 acute-phase protein and interleukin-6 levels in periodontal disease.","date":"2014","source":"Journal of periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/24635545","citation_count":40,"is_preprint":false},{"pmid":"27350398","id":"PMC_27350398","title":"Mycobacteriophage SWU1 gp39 can potentiate multiple antibiotics against Mycobacterium via altering the cell wall permeability.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27350398","citation_count":38,"is_preprint":false},{"pmid":"38320988","id":"PMC_38320988","title":"A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38320988","citation_count":36,"is_preprint":false},{"pmid":"34758182","id":"PMC_34758182","title":"A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34758182","citation_count":36,"is_preprint":false},{"pmid":"8642687","id":"PMC_8642687","title":"Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice.","date":"1996","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8642687","citation_count":36,"is_preprint":false},{"pmid":"32344399","id":"PMC_32344399","title":"Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.","date":"2020","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/32344399","citation_count":35,"is_preprint":false},{"pmid":"30498395","id":"PMC_30498395","title":"Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk.","date":"2018","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/30498395","citation_count":34,"is_preprint":false},{"pmid":"33688211","id":"PMC_33688211","title":"LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33688211","citation_count":34,"is_preprint":false},{"pmid":"39132842","id":"PMC_39132842","title":"Porphyromonas gingivalis fuels colorectal cancer through CHI3L1-mediated iNKT cell-driven immune evasion.","date":"2024","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/39132842","citation_count":32,"is_preprint":false},{"pmid":"24442412","id":"PMC_24442412","title":"The significance of YKL-40 protein in liver fibrosis.","date":"2014","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/24442412","citation_count":32,"is_preprint":false},{"pmid":"37771779","id":"PMC_37771779","title":"5-aminolevulinate and CHIL3/CHI3L1 treatment amid ischemia aids liver metabolism and reduces ischemia-reperfusion injury.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/37771779","citation_count":31,"is_preprint":false},{"pmid":"16949314","id":"PMC_16949314","title":"HC-gp39 contributes to chondrocyte differentiation by inducing SOX9 and type II collagen expressions.","date":"2006","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/16949314","citation_count":30,"is_preprint":false},{"pmid":"28053085","id":"PMC_28053085","title":"Inhibition of Mammalian Glycoprotein YKL-40: IDENTIFICATION OF THE PHYSIOLOGICAL LIGAND.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28053085","citation_count":29,"is_preprint":false},{"pmid":"38543093","id":"PMC_38543093","title":"The Role of Chitinase-3-like Protein-1 (YKL40) in the Therapy of Cancer and Other Chronic-Inflammation-Related Diseases.","date":"2024","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38543093","citation_count":28,"is_preprint":false},{"pmid":"21029458","id":"PMC_21029458","title":"Resveratrol represses YKL-40 expression in human glioma U87 cells.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21029458","citation_count":28,"is_preprint":false},{"pmid":"7532456","id":"PMC_7532456","title":"The expansive role of CD40 and its ligand, gp39, in immunity.","date":"1994","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7532456","citation_count":27,"is_preprint":false},{"pmid":"29477911","id":"PMC_29477911","title":"Angiogenic potential of YKL-40 in the dynamics of tumor niche.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29477911","citation_count":27,"is_preprint":false},{"pmid":"31536166","id":"PMC_31536166","title":"CHI3L1 promotes proliferation and improves sensitivity to cetuximab in colon cancer cells by down-regulating p53.","date":"2019","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/31536166","citation_count":26,"is_preprint":false},{"pmid":"36618349","id":"PMC_36618349","title":"CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36618349","citation_count":25,"is_preprint":false},{"pmid":"34164774","id":"PMC_34164774","title":"Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/34164774","citation_count":25,"is_preprint":false},{"pmid":"7532462","id":"PMC_7532462","title":"The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.","date":"1994","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7532462","citation_count":24,"is_preprint":false},{"pmid":"32045356","id":"PMC_32045356","title":"YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation.","date":"2020","source":"Reviews in the neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/32045356","citation_count":24,"is_preprint":false},{"pmid":"34466014","id":"PMC_34466014","title":"Nrf2 Regulates CHI3L1 to Suppress Inflammation and Improve Post-Traumatic Osteoarthritis.","date":"2021","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/34466014","citation_count":24,"is_preprint":false},{"pmid":"36064078","id":"PMC_36064078","title":"Chi3L1 is a therapeutic target in bone metabolism and a potential clinical marker in patients with osteoporosis.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/36064078","citation_count":24,"is_preprint":false},{"pmid":"38733586","id":"PMC_38733586","title":"Astrocyte-derived CHI3L1 signaling impairs neurogenesis and cognition in the demyelinated hippocampus.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38733586","citation_count":23,"is_preprint":false},{"pmid":"32286145","id":"PMC_32286145","title":"YKL-40 mediates airway remodeling in asthma via activating FAK and MAPK signaling pathway.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/32286145","citation_count":23,"is_preprint":false},{"pmid":"9620168","id":"PMC_9620168","title":"Purification of guinea pig YKL40 and modulation of its secretion by cultured articular chondrocytes.","date":"1998","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9620168","citation_count":23,"is_preprint":false},{"pmid":"20499402","id":"PMC_20499402","title":"Association between YKL-40 and adult primary astrocytoma.","date":"2010","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20499402","citation_count":23,"is_preprint":false},{"pmid":"38271182","id":"PMC_38271182","title":"Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes.","date":"2024","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38271182","citation_count":22,"is_preprint":false},{"pmid":"24981110","id":"PMC_24981110","title":"Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells.","date":"2014","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24981110","citation_count":22,"is_preprint":false},{"pmid":"21987626","id":"PMC_21987626","title":"YKL-40 expression in CD14⁺ liver cells in acute and chronic injury.","date":"2011","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21987626","citation_count":22,"is_preprint":false},{"pmid":"28739286","id":"PMC_28739286","title":"Genetic and epigenetic regulation of YKL-40 in childhood.","date":"2017","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28739286","citation_count":22,"is_preprint":false},{"pmid":"38290090","id":"PMC_38290090","title":"Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia.","date":"2024","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38290090","citation_count":21,"is_preprint":false},{"pmid":"24809021","id":"PMC_24809021","title":"Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.","date":"2014","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24809021","citation_count":21,"is_preprint":false},{"pmid":"7554469","id":"PMC_7554469","title":"The role of gp39 (CD40L) in immunity.","date":"1995","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/7554469","citation_count":20,"is_preprint":false},{"pmid":"37838657","id":"PMC_37838657","title":"Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37838657","citation_count":20,"is_preprint":false},{"pmid":"29848684","id":"PMC_29848684","title":"The Role of CHI3L1 Expression in Angiogenesis in Invasive Ductal Breast Carcinoma.","date":"2018","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29848684","citation_count":20,"is_preprint":false},{"pmid":"37215572","id":"PMC_37215572","title":"Induction of ER stress-mediated apoptosis through SOD1 upregulation by deficiency of CHI3L1 inhibits lung metastasis.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/37215572","citation_count":20,"is_preprint":false},{"pmid":"35342020","id":"PMC_35342020","title":"Further evidence for association of YKL-40 with severe asthma airway remodeling.","date":"2022","source":"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35342020","citation_count":19,"is_preprint":false},{"pmid":"34669813","id":"PMC_34669813","title":"Serum YKL-40 levels in patients with multiple sclerosis.","date":"2021","source":"Arquivos de neuro-psiquiatria","url":"https://pubmed.ncbi.nlm.nih.gov/34669813","citation_count":19,"is_preprint":false},{"pmid":"39933531","id":"PMC_39933531","title":"STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma.","date":"2025","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/39933531","citation_count":18,"is_preprint":false},{"pmid":"26528182","id":"PMC_26528182","title":"Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells.","date":"2015","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26528182","citation_count":18,"is_preprint":false},{"pmid":"34259106","id":"PMC_34259106","title":"YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition.","date":"2021","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34259106","citation_count":18,"is_preprint":false},{"pmid":"18091378","id":"PMC_18091378","title":"YKL-40 expression in benign and malignant lesions of the breast: a methodologic study.","date":"2007","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/18091378","citation_count":18,"is_preprint":false},{"pmid":"28026831","id":"PMC_28026831","title":"The role of YKL-40 in a cancerous process.","date":"2016","source":"Postepy higieny i medycyny doswiadczalnej (Online)","url":"https://pubmed.ncbi.nlm.nih.gov/28026831","citation_count":17,"is_preprint":false},{"pmid":"30543919","id":"PMC_30543919","title":"The loss of tolerance to CHI3L1 - A putative role in inflammatory bowel disease?","date":"2018","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/30543919","citation_count":17,"is_preprint":false},{"pmid":"29400369","id":"PMC_29400369","title":"Correlation between protein YKL-40 and ultrasonographic findings in active knee osteoarthritis.","date":"2018","source":"Medical ultrasonography","url":"https://pubmed.ncbi.nlm.nih.gov/29400369","citation_count":17,"is_preprint":false},{"pmid":"38042775","id":"PMC_38042775","title":"Astrocyte-specific knockout of YKL-40/Chi3l1 reduces Aβ burden and restores memory functions in 5xFAD mice.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/38042775","citation_count":17,"is_preprint":false},{"pmid":"31997395","id":"PMC_31997395","title":"Inflammatory-sensitive CHI3L1 protects nucleus pulposus via AKT3 signaling during intervertebral disc degeneration.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31997395","citation_count":17,"is_preprint":false},{"pmid":"20926018","id":"PMC_20926018","title":"YKL-40 protein levels and clinical outcome of human endometrial cancer.","date":"2010","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/20926018","citation_count":17,"is_preprint":false},{"pmid":"28498006","id":"PMC_28498006","title":"Serum YKL-40 as a potential biomarker of inflammation in psoriasis.","date":"2017","source":"The Journal of dermatological treatment","url":"https://pubmed.ncbi.nlm.nih.gov/28498006","citation_count":17,"is_preprint":false},{"pmid":"32592365","id":"PMC_32592365","title":"Clinical Potentials of miR-576-3p, miR-613, NDRG2 and YKL40 in Colorectal Cancer Patients.","date":"2020","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/32592365","citation_count":16,"is_preprint":false},{"pmid":"35222369","id":"PMC_35222369","title":"Longitudinal and Comparative Measures of Serum Chitotriosidase and YKL-40 in Patients With Idiopathic Pulmonary Fibrosis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35222369","citation_count":16,"is_preprint":false},{"pmid":"31358474","id":"PMC_31358474","title":"Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease.","date":"2019","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31358474","citation_count":16,"is_preprint":false},{"pmid":"32279122","id":"PMC_32279122","title":"Astrocytic IGFBP2 and CHI3L1 in cerebrospinal fluid drive cortical metastasis of HER2+breast cancer.","date":"2020","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/32279122","citation_count":16,"is_preprint":false},{"pmid":"32820151","id":"PMC_32820151","title":"The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32820151","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52376,"output_tokens":6860,"usd":0.130014},"stage2":{"model":"claude-opus-4-6","input_tokens":10592,"output_tokens":3547,"usd":0.212452},"total_usd":0.342466,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"CHI3L1 (YKL-40) secreted by M2 macrophages binds to IL-13Rα2 on cancer cell plasma membranes, activating MAPK signaling and upregulating matrix metalloproteinase gene expression to promote gastric and breast cancer metastasis.\",\n      \"method\": \"GST pull-down assay identifying IL-13Rα2 as receptor; in vitro and in vivo metastasis models; western blot for MAPK pathway activation\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding assay plus in vivo validation with multiple orthogonal methods\",\n      \"pmids\": [\"28143526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CHI3L1 regulates PD-L1, PD-L2, PD-1, LAG3, and TIM3 expression in melanoma and macrophages; IFN-γ-stimulated macrophage PD-L1 expression is dependent on CHI3L1; RIG-like helicase innate immunity suppresses CHI3L1 and PD-L1. Bispecific antibodies simultaneously targeting CHI3L1 and PD-1 show synergistic antitumor effects in T cell-tumor cell cocultures and in vivo metastasis models.\",\n      \"method\": \"Antibody blockade, T cell-tumor cell coculture cytotoxicity assay, in vivo melanoma metastasis models, gene expression analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in vitro and in vivo with mechanistic pathway identification\",\n      \"pmids\": [\"34720089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CHI3L1 promotes neutrophil recruitment and neutrophil extracellular trap (NET) formation in triple-negative breast cancer, which blocks CD8+ T cell tumor infiltration. Chi3l1 expression is regulated downstream of Stat3 in breast tumors.\",\n      \"method\": \"Chi3l1 ablation in PyMT breast cancer mouse model; immune cell infiltration analysis; NET formation assays; Stat3 knockout tumor profiling\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation model with specific cellular phenotype and mechanistic pathway placement\",\n      \"pmids\": [\"38039967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Chi3l1 deletion in mice suppresses glial phagocytic activation; Chi3l1 knockdown increases phagocytosis of zymosan particles and β-amyloid peptide in astrocytes and microglia in vitro, and decreases amyloid plaque burden in APP/PS1 mice. Chi3l1 expression is regulated by the circadian clock via BMAL1/CLOCK/NPAS2 and PER1/PER2.\",\n      \"method\": \"Chi3l1 knockout mice crossed with APP/PS1 AD model; in vitro phagocytosis assay; circadian clock gene deletion; inflammatory induction experiments in astrocytes\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including genetic knockout, in vitro assays, and in vivo AD model with specific phenotypic readouts\",\n      \"pmids\": [\"33328329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cytokine-driven YKL-40 expression in astrocytes requires both STAT3 and NF-κB binding elements of the YKL-40 promoter; specifically IL-1 and oncostatin M promote RelB/p50 complex formation which directly binds the YKL-40 promoter. Expression is independent of p65 NF-κB subunit.\",\n      \"method\": \"Promoter reporter assays, dominant-negative IκBα, constitutively active STAT3, chromatin immunoprecipitation for RelB/p50 binding to YKL-40 promoter, primary human and mouse astrocytes\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — promoter mutagenesis, direct ChIP of transcription factor binding, multiple cell systems\",\n      \"pmids\": [\"25681350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Chi3l1 binds CD44 on glioma stem cells (GSCs) and induces phosphorylation and nuclear translocation of β-catenin, Akt, and STAT3, driving GSCs toward a mesenchymal state. Chi3l1 increases promoter accessibility at MAZ transcription factor sites; MAZ deficiency rescues Chi3L1-induced increase of GSC self-renewal.\",\n      \"method\": \"Binding assay (Chi3l1 to CD44), phosphorylation western blots, scRNA-seq with RNA velocity, ATAC-seq, MAZ inhibition, in vivo tumor growth with blocking antibody\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding identified, multiple orthogonal methods including ATAC-seq and scRNA-seq, in vivo validation\",\n      \"pmids\": [\"37101376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CHI3L1 secreted by activated astrocytes engages the CRTH2 receptor on neural stem cells and dampens β-catenin signaling, inhibiting proliferation and neuronal differentiation of neural stem cells in the context of neuromyelitis optica (NMO). Blocking CHI3L1/CRTH2/β-catenin restores neurogenesis and improves cognitive deficits.\",\n      \"method\": \"CHI3L1 knockdown in astrocytes (in vitro and in vivo NMO mouse model), neural stem cell proliferation/differentiation assays, β-catenin signaling analysis, CRTH2 blocking experiments\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor identification, signaling mechanism defined, in vivo rescue with multiple readouts\",\n      \"pmids\": [\"37756391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Astrocyte-derived CHI3L1 interacts with CRTH2/RAGE receptors and attenuates β-catenin signaling in the demyelinated hippocampus, impairing neural stem cell proliferation, neuronal differentiation, dendritic growth, and spine formation. Astrocytic deletion of CHI3L1 mitigates neurogenic deficits and cognitive dysfunction.\",\n      \"method\": \"Astrocyte-specific CHI3L1 deletion in demyelination mouse model, receptor co-immunoprecipitation (CRTH2/RAGE), β-catenin signaling assays, neural stem cell assays, cognitive behavioral tests\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor interaction identified, signaling mechanism, astrocyte-specific KO with defined cellular and behavioral phenotype\",\n      \"pmids\": [\"38733586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CHI3L1 interacts with BMPRIa on osteoblasts, increasing surface expression of BMPRIa and promoting BMP2 signaling and RUNX2 expression to induce osteoblast differentiation. Chi3l1 KO mice show impaired osteoblast differentiation and aging-related osteoporosis with decreased OPG and increased osteoclast numbers.\",\n      \"method\": \"Co-immunoprecipitation of Chi3l1 with BMPRIa, Chi3l1 KO mouse bone phenotype, primary osteoblast differentiation assays, western blot for BMP2 signaling\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP identifying binding partner, KO mouse model with defined bone phenotype, signaling pathway analysis\",\n      \"pmids\": [\"36064078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CHI3L1 activates AKT3 signaling in nucleus pulposus (NP) cells to protect against intervertebral disc degeneration. CHI3L1 expression is NP tissue-specific and increases during degeneration; overexpression decreases catabolism and increases anabolism of extracellular matrix via AKT3.\",\n      \"method\": \"High-throughput label-free proteomics, RNA sequencing, CHI3L1 overexpression and siRNA knockdown in NP cells, AKT3 phosphorylation analysis, validation in human and mouse degenerated NP tissues\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — proteomic identification, RNA-seq, gain/loss-of-function with specific pathway readout, validated in vivo\",\n      \"pmids\": [\"31997395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A small molecule (K284) that binds to the chitin-binding domain (CBD) of CHI3L1 prevents CHI3L1 binding to IL-13Rα2, thereby suppressing JNK-AP-1 signaling and inhibiting lung metastasis and cancer cell growth.\",\n      \"method\": \"In vitro binding assay of K284 to CHI3L1 CBD, CHI3L1-IL-13Rα2 binding competition assay, JNK-AP-1 signaling analysis, in vitro and in vivo lung metastasis models\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding domain identified, competitive receptor-ligand assay, signaling pathway defined, in vivo validation\",\n      \"pmids\": [\"34758182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"YKL-40 promotes airway remodeling in asthma by increasing airway smooth muscle mass, inducing EMT and sub-epithelial fibrosis through activation of FAK and MAPK signaling pathways. Inhibiting FAK or MAPK significantly ameliorates YKL-40-induced airway remodeling in vitro and in vivo.\",\n      \"method\": \"YKL-40 treatment of airway smooth muscle cells, FAK/MAPK inhibitor experiments, asthma mouse model, EMT marker analysis\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway defined with inhibitor rescue, in vitro and in vivo, single lab\",\n      \"pmids\": [\"32286145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHI3L1 promotes hepatocellular carcinoma cell growth, migration, and invasion by activating TGF-β signaling pathways, including phosphorylation of SMAD2 and SMAD3. CHI3L1 overexpression affects genes involved in cell-cell adhesion, extracellular exosome, and adherens junction.\",\n      \"method\": \"CHI3L1 overexpression in HCC cell lines, RNA-seq gene expression profiling, western blot for SMAD2/3 phosphorylation, in vivo tumor models\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with RNA-seq and signaling validation, in vivo confirmation, single lab\",\n      \"pmids\": [\"30301907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HC-gp39 (CHI3L1) induces SOX9 and type II collagen expression in chondrocytes via MAP kinase (ERK1/2 phosphorylation) and PI3 kinase (AKT phosphorylation) signaling pathways, promoting chondrocyte differentiation.\",\n      \"method\": \"Purified HC-gp39 treatment of primary neonatal mouse rib chondrocytes, phosphorylation-specific western blot, selective signaling inhibitors\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway defined with inhibitors and phosphoprotein analysis, single lab\",\n      \"pmids\": [\"16949314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"YKL-40-expressing M2-like macrophages in gallbladder cancer induce tumor cell secretion of GDF15, which cooperates with YKL-40 to promote PD-L1 expression via PI3K, AKT, and/or Erk activation, leading to T cell cytotoxicity inhibition and tumor immune evasion. YKL-40 shRNA reprogrammed M2-like THP-1 cells to M1-like macrophages.\",\n      \"method\": \"Single-cell transcriptome analysis, YKL-40 shRNA knockdown, PI3K/AKT/Erk signaling analysis by western blot, co-culture assays for T cell function\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway defined, single-cell RNA-seq, shRNA knockdown with phenotypic readout, single lab\",\n      \"pmids\": [\"37088328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CHI3L1 directly binds the coiled-coil domain (CCD) of STAT3 to enhance its phosphorylation, nuclear localization, and transcriptional activity. CHI3L1 and OPN/ITGB1 form a positive feedback loop maintaining NF-κB and STAT3 pathway activation in glioblastoma mesenchymal transition. Hygromycin B disrupts the CHI3L1-STAT3 interaction.\",\n      \"method\": \"scMulti-omics, direct binding assay of CHI3L1 to STAT3 CCD, phosphorylation and nuclear localization analysis, C57BL/6 and NSG mouse tumor models, pharmacological inhibition with hygromycin B\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct protein-domain binding identified, mechanistic pathway in vitro and in vivo, pharmacological validation\",\n      \"pmids\": [\"39933531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"YKL-40 knockdown (siRNA) in glioblastoma U87 cells arrests the cell cycle in G1 phase and decreases phosphorylated ERK1/2 and AKT levels. YKL-40 promotes glioma cell proliferation through activation of MAPK and AKT pathways; resveratrol represses YKL-40 via the ERK1/2 pathway.\",\n      \"method\": \"siRNA knockdown, flow cytometry cell cycle analysis, western blot for phospho-ERK1/2, phospho-AKT, p38 MAPK inhibitor (SB203580) rescue experiments\",\n      \"journal\": \"Cancer; BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with pathway readout, pharmacological inhibitor rescue, replicated across two studies\",\n      \"pmids\": [\"20499402\", \"21029458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CHI3L1 depletion in cancer cells induces ER stress through PERK-eIF2α-ATF4 signaling activation, leading to ER stress-mediated apoptosis. CHI3L1 is localized in the ER. Superoxide dismutase-1 (SOD1) was identified as a novel interacting protein of CHI3L1; CHI3L1 depletion increases SOD1 expression resulting in ER stress and apoptosis in cancer cells.\",\n      \"method\": \"LC-MS/MS proteomics in CHI3L1-overexpressing cells, co-immunoprecipitation of CHI3L1 and SOD1, ER stress marker analysis, CHI3L1-KO mouse tumor models, SOD1 siRNA rescue experiments\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — MS-based interactome, co-IP for binding partner, in vivo KO model, rescue experiments, multiple orthogonal methods\",\n      \"pmids\": [\"37215572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Anti-CHI3L1 antibody inhibits lung tumor growth and metastasis by blocking STAT6-dependent M2 macrophage polarization. Proteomics analysis revealed that plasminogen (PLG) interacts with CHI3L1 and affects M2 polarization.\",\n      \"method\": \"Anti-CHI3L1 humanized antibody in lung cancer mouse model, STAT6 pathway analysis, proteomics identification of PLG-CHI3L1 interaction\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo antibody blockade with defined pathway, proteomics-identified binding partner, single lab\",\n      \"pmids\": [\"34861103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHI3L1 inhibits ICOS, ICOSL, and CD28 expression while stimulating CTLA-4 and B7 ligands in melanoma lung metastasis. Bispecific antibodies targeting both CHI3L1 and CTLA-4 synergistically induce cytotoxic T cell-mediated tumor cell death and heighten PTEN expression.\",\n      \"method\": \"CHI3L1 antibody blockade, T cell-tumor cell cocultures, melanoma lung metastasis mouse model, bispecific antibody treatment, flow cytometry for checkpoint markers\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional cell assays, in vivo model, checkpoint marker regulation defined, single lab\",\n      \"pmids\": [\"36618349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"pSTAT3+ reactive astrocytes secrete CHI3L1 (a STAT3 transcriptional target) at the brain-tumor interface; this CHI3L1 promotes highly invasive brain metastasis invasion into the brain parenchyma. Recombinant CHI3L1 alone or STAT3 activation induced cancer cell invasion into brain parenchyma in a brain slice-tumor co-culture assay.\",\n      \"method\": \"Single-cell RNA sequencing, immunohistochemistry, STAT3 inhibition and genetic ablation, brain slice-tumor plug co-culture invasion assay, PDX and syngeneic mouse models\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — STAT3 as upstream transcriptional regulator of CHI3L1 established, recombinant protein functional assay, genetic ablation, in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"38271182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CHI3L1 gene expression functionally influences tumor microtube (TM) network connectivity in glioblastoma; Chi3l1 serves as a robust molecular marker of TM connectivity associated with the mesenchymal subtype.\",\n      \"method\": \"scRNA-seq from xenografted primary GB cells with dye uptake connectivity assay, calcium imaging, clinical correlation in large GB cohorts\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional connectivity assay combined with scRNA-seq, validated clinically, single lab\",\n      \"pmids\": [\"38320988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Astrocyte-derived CHI3L1 expression promotes Aβ accumulation by suppressing glial phagocytosis of amyloid. Astrocyte-specific YKL-40 knockout in 5xFAD mice reduces amyloid plaque deposition through enhanced Aβ uptake, increased Aβ degradation rate, and lysosomal acidification in YKL-40 KO astrocytes. In primary neurons, YKL-40 combined with Aβ induces synaptic degeneration and impairs electrical parameters.\",\n      \"method\": \"Astrocyte-specific Chi3l1 KO in 5xFAD mice, primary astrocyte phagocytosis assay, Aβ uptake/degradation assay, lysosomal acidification assay, primary neuron treatment with recombinant YKL-40\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — astrocyte-specific genetic KO in AD model, in vitro mechanistic assays for phagocytosis and lysosomal function, multiple orthogonal methods\",\n      \"pmids\": [\"38042775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Molecular dynamics simulations predict that hyaluronan is the preferred physiological ligand for YKL-40 over chito-oligosaccharides and collagen-like peptides, based on calculated free energies of binding. Heparin binds non-specifically at the YKL-40 surface.\",\n      \"method\": \"Molecular dynamics simulations with free energy calculations for multiple ligands\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no experimental validation\",\n      \"pmids\": [\"28053085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"P. gingivalis increases CHI3L1 expression in iNKT cells, impairing their cytotoxic (lytic) functions and promoting colorectal cancer immune evasion. Neutralization of CHI3L1 restored iNKT cell cytotoxic functions.\",\n      \"method\": \"In vivo P. gingivalis CRC mouse model, in vitro iNKT cell stimulation assays, CHI3L1 neutralizing antibody, cytotoxicity assays\",\n      \"journal\": \"Gut microbes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro models, neutralization rescue, defined cellular mechanism, single lab\",\n      \"pmids\": [\"39132842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Nrf2 overexpression suppresses CHI3L1 expression in synoviocytes stimulated with LPS; LPS-induced CHI3L1 increase correlates with ROS and inflammatory cytokine (TNF-α, IL-1β, IL-6) production. Nrf2 acts as a negative regulator of CHI3L1 in post-traumatic osteoarthritis.\",\n      \"method\": \"Nrf2 overexpression lentiviral vector in PTOA mouse model (intra-articular injection), LPS-stimulated murine synoviocyte in vitro model, ELISA/western blot for CHI3L1 and inflammatory markers\",\n      \"journal\": \"Journal of inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function in vivo and in vitro with defined regulatory relationship, single lab\",\n      \"pmids\": [\"34466014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"M2 macrophage-secreted CHI3L1 promotes hepatocyte recovery from ischemia-reperfusion injury by improving hepatocellular lipid metabolism. Downstream of CX3CR1 deficiency and RelA suppression, M2 macrophages upregulate CHIL3/CHI3L1 which improves mitochondrial function and reduces injury in cultured hepatocytes.\",\n      \"method\": \"CX3CR1 KO mice, 5-ALA treatment, M2 macrophage polarization assay, hepatocyte co-culture with recombinant CHIL3/CHI3L1, metabolic and mitochondrial function assays\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO model, recombinant protein treatment, mechanistic pathway identified, single lab\",\n      \"pmids\": [\"37771779\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CHI3L1/YKL-40 is a secreted, chitin-binding glycoprotein (lacking catalytic chitinase activity) produced by activated astrocytes, macrophages, and tumor cells that acts extracellularly through multiple receptors—including IL-13Rα2, CD44, CRTH2, RAGE, and BMPRIa—to activate downstream signaling cascades (MAPK, PI3K/AKT, STAT3, NF-κB/RelB/p50, TGF-β/SMAD, BMP2, β-catenin, and JNK-AP-1), regulate innate immune cell polarization (M2 macrophage programming, neutrophil NET formation), suppress glial and neural stem cell phagocytic/neurogenic activity, modulate immune checkpoint expression (PD-L1, CTLA-4), and promote tumor invasion, metastasis, and extracellular matrix remodeling; its transcription is regulated by IL-1/IL-6 family cytokines via STAT3 and RelB/p50 complexes, and by the circadian clock via BMAL1/CLOCK.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CHI3L1 (YKL-40) is a secreted glycoprotein lacking chitinase catalytic activity that functions as a multireceptor ligand to regulate innate immunity, tissue remodeling, and tumor progression across diverse cellular contexts. It signals through IL-13Rα2 to activate MAPK and JNK-AP-1 pathways promoting cancer metastasis [PMID:28143526, PMID:34758182], through CD44 to drive β-catenin/Akt/STAT3-dependent glioma stem cell self-renewal [PMID:37101376], and through CRTH2/RAGE to suppress β-catenin signaling and inhibit neural stem cell neurogenesis [PMID:37756391, PMID:38733586]; it also directly binds the STAT3 coiled-coil domain to enhance STAT3 phosphorylation and nuclear translocation in glioblastoma [PMID:39933531]. In the immune microenvironment, CHI3L1 promotes M2 macrophage polarization, neutrophil extracellular trap formation that excludes CD8+ T cells, and upregulation of immune checkpoint molecules including PD-L1 and CTLA-4 [PMID:34720089, PMID:38039967, PMID:36618349]; in astrocytes, it suppresses phagocytic clearance of amyloid-β, and its transcription is controlled by STAT3, RelB/p50 NF-κB complexes, and the BMAL1/CLOCK circadian machinery [PMID:25681350, PMID:33328329, PMID:38042775].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing that CHI3L1 is not merely a biomarker but an active signaling ligand: exogenous HC-gp39 induced SOX9 and collagen II in chondrocytes through ERK1/2 and AKT phosphorylation, demonstrating that the catalytically inactive lectin has direct cell-signaling capacity.\",\n      \"evidence\": \"Purified protein treatment of primary chondrocytes with pharmacological inhibitors and phospho-western blot\",\n      \"pmids\": [\"16949314\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating chondrocyte signaling was not identified\", \"Mechanism of downstream SOX9 transcription not resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Loss-of-function studies confirmed CHI3L1 as a cell-autonomous driver of glioblastoma proliferation via MAPK/AKT, linking the secreted protein to tumor cell cycle progression.\",\n      \"evidence\": \"siRNA knockdown in U87 glioblastoma cells with cell cycle analysis and phospho-ERK/AKT western blot\",\n      \"pmids\": [\"20499402\", \"21029458\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor(s) on glioblastoma cells mediating autocrine signaling not identified\", \"Downstream transcriptional targets driving G1 arrest not characterized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The transcriptional logic of CHI3L1 induction was resolved: IL-1/oncostatin M-driven expression in astrocytes requires cooperative STAT3 and RelB/p50 NF-κB promoter engagement, with RelB/p50 (not p65) directly binding the CHI3L1 promoter.\",\n      \"evidence\": \"Promoter-reporter mutagenesis, ChIP for RelB/p50, dominant-negative IκBα in primary human and mouse astrocytes\",\n      \"pmids\": [\"25681350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RelB/p50 regulation operates in non-astrocyte cell types not tested\", \"Epigenetic regulation of the locus not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The first bona fide cell-surface receptor for CHI3L1 was identified: IL-13Rα2 on cancer cells, establishing a ligand-receptor axis by which M2 macrophage-derived CHI3L1 activates MAPK signaling to drive metastasis.\",\n      \"evidence\": \"GST pull-down identifying IL-13Rα2, MAPK pathway activation by western blot, in vivo metastasis models\",\n      \"pmids\": [\"28143526\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IL-13Rα2 mediates CHI3L1 signaling in non-cancer contexts not established\", \"Co-receptors or adaptor mechanisms downstream of IL-13Rα2 not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CHI3L1 was established as a suppressor of glial phagocytosis relevant to Alzheimer's disease, and its expression was linked to circadian clock control via BMAL1/CLOCK, revealing a time-of-day dimension to its regulation.\",\n      \"evidence\": \"Chi3l1 KO crossed with APP/PS1 mice; in vitro phagocytosis of Aβ/zymosan; circadian gene deletion in astrocytes\",\n      \"pmids\": [\"33328329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor through which CHI3L1 suppresses phagocytosis not identified in this study\", \"Mechanism linking circadian transcription factors to CHI3L1 promoter occupancy not shown by ChIP\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CHI3L1 was revealed as an upstream regulator of immune checkpoint molecules (PD-L1, PD-1, LAG3, TIM3), establishing it as an immunomodulatory node that could be co-targeted with checkpoint blockade for synergistic anti-tumor effects.\",\n      \"evidence\": \"Antibody blockade, T cell–tumor coculture cytotoxicity, in vivo melanoma metastasis, bispecific CHI3L1/PD-1 antibody\",\n      \"pmids\": [\"34720089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway connecting CHI3L1 to transcriptional regulation of PD-L1/LAG3/TIM3 not fully defined\", \"Whether checkpoint regulation is receptor-specific or shared across CHI3L1 receptors unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A second receptor axis was defined: CHI3L1 binds BMPRIa on osteoblasts to potentiate BMP2/RUNX2 osteoblast differentiation, and Chi3l1 KO mice develop osteoporosis, demonstrating a physiological role beyond inflammation and cancer.\",\n      \"evidence\": \"Co-immunoprecipitation of Chi3l1–BMPRIa, Chi3l1 KO bone phenotyping, primary osteoblast differentiation assays\",\n      \"pmids\": [\"36064078\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CHI3L1–BMPRIa interaction not resolved\", \"Whether BMPRIa mediates CHI3L1 signaling in non-bone tissues not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The chitin-binding domain was validated as a druggable surface: a small molecule (K284) competitively blocks CHI3L1 binding to IL-13Rα2, suppressing JNK-AP-1 signaling and lung metastasis.\",\n      \"evidence\": \"In vitro binding and competition assays, JNK-AP-1 signaling analysis, in vivo lung metastasis models\",\n      \"pmids\": [\"34758182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity of K284 for CHI3L1 over other GH18 family members not shown\", \"Whether K284 blocks CHI3L1 binding to other receptors (CD44, CRTH2, BMPRIa) not assessed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Additional receptor diversity was uncovered: CHI3L1 engages CD44 on glioma stem cells to activate β-catenin/Akt/STAT3, chromatin remodeling at MAZ sites, and mesenchymal transition; and CRTH2 on neural stem cells to suppress β-catenin-dependent neurogenesis.\",\n      \"evidence\": \"Binding assays, ATAC-seq, scRNA-seq with RNA velocity for CD44 axis; CRTH2 blocking, β-catenin analysis, NMO mouse model for CRTH2 axis\",\n      \"pmids\": [\"37101376\", \"37756391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural determinants distinguishing CHI3L1 binding to CD44 vs. CRTH2 unknown\", \"Whether CHI3L1 signals through CD44 and CRTH2 simultaneously on the same cell not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"In the tumor immune microenvironment, CHI3L1 was shown to promote neutrophil recruitment and NET formation that physically excludes CD8+ T cells, establishing a STAT3-CHI3L1-NET immunosuppressive circuit in triple-negative breast cancer.\",\n      \"evidence\": \"Chi3l1 genetic ablation in PyMT breast cancer model, immune cell infiltration analysis, NET assays, Stat3 KO tumor profiling\",\n      \"pmids\": [\"38039967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor on neutrophils that mediates CHI3L1-induced NET formation not identified\", \"Whether CHI3L1-driven NETs operate in non-breast tumor types not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"An intracellular role emerged: CHI3L1 resides in the ER and interacts with SOD1; its depletion triggers PERK-eIF2α-ATF4 ER stress-mediated apoptosis, suggesting functions beyond secreted signaling.\",\n      \"evidence\": \"LC-MS/MS proteomics, co-IP of CHI3L1–SOD1, ER stress marker analysis, CHI3L1-KO mouse tumors, SOD1 siRNA rescue\",\n      \"pmids\": [\"37215572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER-resident CHI3L1 is a distinct pool from secreted CHI3L1 not clarified\", \"Structural basis of CHI3L1–SOD1 interaction unknown\", \"Generalizability of ER stress phenotype to non-cancer cells not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A direct intracellular signaling mechanism was identified: CHI3L1 binds the coiled-coil domain of STAT3 to promote its phosphorylation and nuclear translocation, forming a positive feedback loop with OPN/ITGB1 and NF-κB in glioblastoma mesenchymal transition.\",\n      \"evidence\": \"scMulti-omics, domain-specific binding assays, phosphorylation/nuclear localization analysis, hygromycin B as pharmacological disruptor, mouse tumor models\",\n      \"pmids\": [\"39933531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether direct CHI3L1–STAT3 binding occurs in non-glioblastoma cells unknown\", \"How CHI3L1 accesses intracellular STAT3 (internalization vs. de novo synthesis) not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include: (1) how CHI3L1 selects among its multiple receptors (IL-13Rα2, CD44, CRTH2, RAGE, BMPRIa) in different cellular contexts; (2) whether its intracellular ER/STAT3-binding functions are independent of its secreted extracellular receptor-mediated signaling; and (3) whether a unifying structural model explains differential ligand-receptor engagement through the chitin-binding domain.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural co-crystal with any receptor\", \"No systematic comparison of receptor affinities or competition\", \"Intracellular vs. extracellular functional partitioning not delineated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 5, 6, 7, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 14, 19]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 6, 8, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 6, 7, 8, 9, 22]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 6, 7, 8, 10, 13, 15, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 14, 18, 19, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 2, 5, 12, 15, 20, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"IL13RA2\",\n      \"CD44\",\n      \"PTGDR2\",\n      \"AGER\",\n      \"BMPR1A\",\n      \"STAT3\",\n      \"SOD1\",\n      \"PLG\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}